BROOKS, PETER,CHERESH, DAVID A.,FRIEDLANDER, MARTIN
申请号：
CA2227265
公开号：
CA2227265C
申请日:
1996.08.13
申请国别(地区):
CA
年份:
2012
代理人:
摘要：
The present invention describes methods for inhibiting angiogenesis in tissuesusing vitronectin .alpha.v.beta.5 antagonists. The .alpha.v.beta.5-mediatedangiogenesis is correlated with exposure to cytokines including vascularendothelial growth factor, transforming growth factor-.alpha. and epidermalgrowth factor. Inhibition of .alpha.v.beta.5-mediated angiogenesis isparticularly preferred in vascular endothelial ocular neovascular diseases, intumor growth and in inflammatory conditions, using therapeutic compositionscontaining .alpha.v.beta.5 antagonists.
